Ibudilast in relapsing-remitting multiple sclerosis: A neuroprotectant?
The DOI matches its Crossref record.
Abstract
BACKGROUND: Ibudilast is a phosphodiesterase inhibitor influencing inflammation and neurodegeneration in multiple sclerosis (MS). This study evaluated the safety, tolerability, and effects on MRI parameters of 2 different doses of ibudilast in relapsing forms of MS. METHODS: In this multicenter, double-blind, phase 2 trial, patients with relapsing MS and gadolinium-enhancing lesions were randomly assigned 1:1:1 to receive 30 or 60 mg ibudilast or placebo every day for 12 months. The primary endpoint was the cumulative number of newly active lesions on bimonthly brain MRI over 12 months. Secondary endpoints included relapse rate, change in Expanded Disability Status Scale (EDSS) score, T2-hyperintense and T1-hypointense lesion volumes, and percent brain volume change (PBVC). RESULTS: A total of 297 patients were randomized in 19 centers. During the first 12 months, the mean number of active lesions and relapse rate did not differ between treatment arms. A reduction in PBVC (p = 0.04) was found in the 60-mg group (0.8%) compared with placebo (1.2%). Post hoc analysis showed a reduction in the proportion active lesions that evolved into persistent black holes for the 60-mg (0.14; p = 0.004) and 30-mg (0.17; p = 0.036) groups compared with the placebo group (0.24). Over 2 years, there were fewer patients (p = 0.026) with confirmed progression on the EDSS. Treatment with ibudilast was generally safe and well tolerated. CONCLUSION: Ibudilast showed no beneficial effect on the rate of newly active lesions and relapses. However, preliminary evidence suggests that ibudilast seems to act in a neuroprotective fashion as measured by 2 independent MRI outcomes, with a possible beneficial clinical effect on disability progression. CLASSIFICATION OF EVIDENCE: This interventional study provides Class III evidence on the effect of ibudilast on disease activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
(1973) · BMJ · doi:10.1136/bmj.2.5863.432 · Cited by 488
Old Drugs as New Treatments for Neurodegenerative Diseases
Durães, F., Pinto, M., & Sousa, E. (2018) · Pharmaceuticals · doi:10.3390/ph11020044 · Cited by 343
Clinical Relevance of Brain Volume Measures in Multiple Sclerosis
De Stefano, N., Airas, L., Grigoriadis, N., Mattle, H. P., O’Riordan, J., Oreja-Guevara, C., Sellebjerg, F., Stankoff, B., Walczak, A., Wiendl, H., et al. (2014) · CNS Drugs · doi:10.1007/s40263-014-0140-z · Cited by 301
Disability, atrophy and cortical reorganization following spinal cord injury
Freund, P., Weiskopf, N., Ward, N. S., Hutton, C., Gall, A., Ciccarelli, O., Craggs, M., Friston, K., & Thompson, A. J. (2011) · Brain · doi:10.1093/brain/awr093 · Cited by 294
Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis
Fox, R. J., Coffey, C. S., Conwit, R., Cudkowicz, M. E., Gleason, T., Goodman, A., Klawiter, E. C., Matsuda, K., McGovern, M., Naismith, R. T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1803583 · Cited by 286
Self-citation
Metadata
- Authors
- Barkhof, F., Hulst, H. E., Drulović, J., Uitdehaag, B. M. J., Matsuda, K., & Landin, R.
- Venue
- Neurology
- Published
- 2010-03-30
- Volume
- 74
- Issue
- 13
- Pages
- 1033-1040
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2096967123
- Cited by
- 154
- References
- 0
- FWCI
- 8.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ibudilast in relapsing-remitting multiple sclerosis: A neuroprotectant? https://app.cochat.ai/papers/10.1212/wnl.0b013e3181d7d651
- The paper
- Barkhof, F., Hulst, H. E., Drulović, J., Uitdehaag, B. M. J., Matsuda, K., & Landin, R. (2010). Ibudilast in relapsing-remitting multiple sclerosis: A neuroprotectant? Neurology. https://doi.org/10.1212/wnl.0b013e3181d7d651
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.